Marrying Complex Biomarker Validation & CDx Development for Supercharged Precision Oncology Pipeline Commercialization
The 12th World Clinical Biomarkers & CDx Summit returns at a crucial time for the entire precision & targeted drug development industry. Spurred on by a number of recent exciting biomarker-driven therapy and CDx approvals by the FDA, including Eli Lilly’s Verzenio, J&J’s Amivantamab & Takeda’s Mobocertinib, the race to market is becoming ever fiercer to deliver the next-generation of safer & more effective therapies for defined patient populations.
Returning in-person for the first time in three years, hear the latest insights, case studies and technologies enhancing your predictive biomarker discovery, to support next generation CDx development, informed clinical decisions, regulatory approval & a robust go-to market strategy for a breakthrough therapy.
Across 2-days & 3 distinct tracks, this is your only end-to-end biomarker-driven & diagnostic enabled drug development summit, led by 70+ industry leaders triumphing and overcoming challenges to predictive biomarker development and commercialization.
You cannot afford to miss World CB & CDx 2022, as key industry stakeholders gather and leave no stone unturned to advance more life changing precision and targeted drugs to patients.
70+ Expert Speakers Including:
Director, Global Commercial Strategy, Precision Medicine
IVD Product Expert
Office Director, Office of Drug Evaluation Sciences, OND
CDER U.S. Food and Drug Administration
Head of Global Regulatory Affairs, Precision Medicine & Digital Health
Vice President, Head of Biostatistics, Oncology Group
Chief Executive Officer
Director, Precision Medicine Lead
Deputy Branch Chief, Molecular Genetics Branch
CDRH, U.S. Food and Drug Administration
Vice President, Precision Medicine
Bristol Myers Squibb
Vice President, Head Companion Diagnostics, Global Companion Diagnostics, Global Oncology R&D
Senior Director, Clinical Biomarkers
Chief Executive Officer
Why Are Experts Attending in 2022?
"I’m looking forward to attending and presenting at the 12th World Clinical Biomarkers & CDx Summit. This is a key meeting for researchers, biomarker developers and Pharma to connect and shape the future of Precision Medicine."
Amy Gorman, Director, Global Commercial Strategy, Precision Medicine, Janssen
“The Summit uniquely covers the entirety of biomarker discovery and clinical implementation, providing interesting discussions for a wide audience.”
Melinda Day, Associate Director, Translational Clinical Development, Kronos Bio
"This conference has been very insightful in the past as the field of CDx is still advancing and we can learn from each other’s experiences"
Silva Krause, Senior Director, Clinical Biomarkers, Vertex Pharmaceuticals